CompletedNot applicableNCT02037256
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Studying Lymphomatoid granulomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Principal Investigator
- Divaya Bhutani, M.D.Barbara Ann Karmanos Cancer Institute
- Intervention
- bortezomib(drug)
- Enrollment
- 23 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2011 – 2015
Study locations (1)
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02037256 on ClinicalTrials.gov